MedPath

Diagnostic value of methylated SEPT9 and RNF180 for gastric cancer

Completed
Conditions
Collect plasma samples from patients diagnosed with benign gastric diseases and gastric cancer through endoscopic examination and histopathological examination, and evaluate the diagnostic value of mSEPT9 and mRNF180 alone or in combination for gastric cancer.
diagnostic value, gastric cancer, methylation, SEPT9, RNF180
Registration Number
TCTR20240606001
Lead Sponsor
The First Affiliated Hospital of Kunming Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
201
Inclusion Criteria

1) All patients underwent endoscopic examination and histopathological examination, with complete clinical information; 2) Not receiving radiotherapy, chemotherapy, or gastric cancer related surgery; 3) no pregnancy.

Exclusion Criteria

1) Patients who have not undergone endoscopic examination and histopathological examination have incomplete clinical information; 2) Hemolytic samples; 3) Including incomplete history of gastric cancer surgery, other cancer history, or any history of chemotherapy or radiation therapy; 4) Pregnancy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Combined diagnostic accuracy of methylated SEPT9 and RNF180 At the time that patients test with PCR Sensitivity, Specificity, PPV, NPV, AUROC
Secondary Outcome Measures
NameTimeMethod
Independent diagnostic accuracy of methylated SEPT9 or RNF180 At the time that patients test with PCR Sensitivity, Specificity, PPV, NPV, AURO
© Copyright 2025. All Rights Reserved by MedPath